Your browser doesn't support javascript.
loading
Sodium Bicarbonate for Metabolic Acidosis in the ICU: Results of a Pilot Randomized Double-Blind Clinical Trial.
Serpa Neto, Ary; Fujii, Tomoko; McNamara, Mairead; Moore, James; Young, Paul J; Peake, Sandra; Bailey, Michael; Hodgson, Carol; Higgins, Alisa M; See, Emily J; Secombe, Paul; Campbell, Lewis; Young, Meredith; Maeda, Mikihiro; Pilcher, David; Nichol, Alistair; Deane, Adam; Licari, Elisa; White, Kyle; French, Craig; Shehabi, Yahya; Cross, Anthony; Maiden, Matthew; Kadam, Umesh; El Khawas, Khaled; Cooper, Jamie; Bellomo, Rinaldo; Udy, Andrew.
Afiliación
  • Serpa Neto A; Australian and New Zealand Intensive Care Research Centre (ANZIC-RC), School of Public Health and Preventive Medicine, Monash University, Melbourne, VC, Australia.
  • Fujii T; Department of Critical Care, Melbourne Medical School, University of Melbourne, Austin Hospital, Melbourne, VC, Australia.
  • McNamara M; Data Analytics Research and Evaluation (DARE) Centre, Austin Hospital, Melbourne, VC, Australia.
  • Moore J; Department of Critical Care Medicine, Hospital Israelita Albert Einstein, São Paulo, Brazil.
  • Young PJ; Australian and New Zealand Intensive Care Research Centre (ANZIC-RC), School of Public Health and Preventive Medicine, Monash University, Melbourne, VC, Australia.
  • Peake S; Intensive Care Unit, The Jikei University School of Medicine, Tokyo, Japan.
  • Bailey M; Australian and New Zealand Intensive Care Research Centre (ANZIC-RC), School of Public Health and Preventive Medicine, Monash University, Melbourne, VC, Australia.
  • Hodgson C; Intensive Care Unit, Wellington Hospital, Wellington, New Zealand.
  • Higgins AM; Medical Research Institute of New Zealand, Wellington, New Zealand.
  • See EJ; Australian and New Zealand Intensive Care Research Centre (ANZIC-RC), School of Public Health and Preventive Medicine, Monash University, Melbourne, VC, Australia.
  • Secombe P; Department of Critical Care, Melbourne Medical School, University of Melbourne, Austin Hospital, Melbourne, VC, Australia.
  • Campbell L; Intensive Care Unit, Wellington Hospital, Wellington, New Zealand.
  • Young M; Medical Research Institute of New Zealand, Wellington, New Zealand.
  • Maeda M; Australian and New Zealand Intensive Care Research Centre (ANZIC-RC), School of Public Health and Preventive Medicine, Monash University, Melbourne, VC, Australia.
  • Pilcher D; Department of Intensive Care Medicine, The Queen Elizabeth Hospital, Woodville South, SA, Australia.
  • Nichol A; Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, SA, Australia.
  • Deane A; Australian and New Zealand Intensive Care Research Centre (ANZIC-RC), School of Public Health and Preventive Medicine, Monash University, Melbourne, VC, Australia.
  • Licari E; Australian and New Zealand Intensive Care Research Centre (ANZIC-RC), School of Public Health and Preventive Medicine, Monash University, Melbourne, VC, Australia.
  • White K; Australian and New Zealand Intensive Care Research Centre (ANZIC-RC), School of Public Health and Preventive Medicine, Monash University, Melbourne, VC, Australia.
  • French C; Department of Critical Care, Melbourne Medical School, University of Melbourne, Austin Hospital, Melbourne, VC, Australia.
  • Shehabi Y; Department of Intensive Care Medicine, Austin Hospital, Melbourne, VC, Australia.
  • Cross A; Australian and New Zealand Intensive Care Research Centre (ANZIC-RC), School of Public Health and Preventive Medicine, Monash University, Melbourne, VC, Australia.
  • Maiden M; Intensive Care Unit Alice Springs Hospital, Alice Springs, NT, Australia.
  • Kadam U; College of Medicine and Public Health, Flinders University, Bedford Park, SA, Australia.
  • El Khawas K; The Australian and New Zealand Intensive Care Society (ANZICS) Centre for Outcome and Resource Evaluation (CORE), Melbourne, VC, Australia.
  • Cooper J; College of Medicine and Public Health, Flinders University, Bedford Park, SA, Australia.
  • Bellomo R; Intensive Care Unit, Royal Darwin Hospital, Darwin, NT, Australia.
  • Udy A; Department of Intensive Care and Hyperbaric Medicine, The Alfred Hospital, Melbourne, VC, Australia.
Crit Care Med ; 51(11): e221-e233, 2023 11 01.
Article en En | MEDLINE | ID: mdl-37294139
ABSTRACT

OBJECTIVES:

To identify the best population, design of the intervention, and to assess between-group biochemical separation, in preparation for a future phase III trial.

DESIGN:

Investigator-initiated, parallel-group, pilot randomized double-blind trial.

SETTING:

Eight ICUs in Australia, New Zealand, and Japan, with participants recruited from April 2021 to August 2022. PATIENTS Thirty patients greater than or equal to 18 years, within 48 hours of admission to the ICU, receiving a vasopressor, and with metabolic acidosis (pH < 7.30, base excess [BE] < -4 mEq/L, and Pa co2 < 45 mm Hg).

INTERVENTIONS:

Sodium bicarbonate or placebo (5% dextrose). MEASUREMENTS AND MAIN

RESULT:

The primary feasibility aim was to assess eligibility, recruitment rate, protocol compliance, and acid-base group separation. The primary clinical outcome was the number of hours alive and free of vasopressors on day 7. The recruitment rate and the enrollment-to-screening ratio were 1.9 patients per month and 0.13 patients, respectively. Time until BE correction (median difference, -45.86 [95% CI, -63.11 to -28.61] hr; p < 0.001) and pH correction (median difference, -10.69 [95% CI, -19.16 to -2.22] hr; p = 0.020) were shorter in the sodium bicarbonate group, and mean bicarbonate levels in the first 24 hours were higher (median difference, 6.50 [95% CI, 4.18 to 8.82] mmol/L; p < 0.001). Seven days after randomization, patients in the sodium bicarbonate and placebo group had a median of 132.2 (85.6-139.1) and 97.1 (69.3-132.4) hours alive and free of vasopressor, respectively (median difference, 35.07 [95% CI, -9.14 to 79.28]; p = 0.131). Recurrence of metabolic acidosis in the first 7 days of follow-up was lower in the sodium bicarbonate group (3 [20.0%] vs. 15 [100.0%]; p < 0.001). No adverse events were reported.

CONCLUSIONS:

The findings confirm the feasibility of a larger phase III sodium bicarbonate trial; eligibility criteria may require modification to facilitate recruitment.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Acidosis / Bicarbonato de Sodio Tipo de estudio: Clinical_trials / Guideline / Prognostic_studies Límite: Humans País/Región como asunto: Oceania Idioma: En Revista: Crit Care Med Año: 2023 Tipo del documento: Article País de afiliación: Australia

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Acidosis / Bicarbonato de Sodio Tipo de estudio: Clinical_trials / Guideline / Prognostic_studies Límite: Humans País/Región como asunto: Oceania Idioma: En Revista: Crit Care Med Año: 2023 Tipo del documento: Article País de afiliación: Australia